Overnight success proves elusive for oral MS drugs

Theoretically, the advent of oral MS treatments was supposed to drain sales away from less-convenient injectables--and quickly. In practice, patients and doctors have proven more cautious about the newer drugs, The Wall Street Journal reports.The ease of taking a pill isn't seen as much of an advantage, at least not yet. Deciding which type of treatment to use is "all about safety and efficacy, not oral versus needle," Lawrence Steinman, a Stanford University neurologist, told the WSJ. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.